Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort Study.

IF 1.9 4区医学 Q3 ONCOLOGY

Clinical Medicine Insights-Oncology Pub Date : 2025-07-01 eCollection Date: 2025-01-01 DOI:10.1177/11795549251348367

I-Lin Tsai, Chien-Yu Lin, Po-Lan Su, Chien-Chung Lin, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Cheng-Ta Yang, Chiao-En Wu

{"title":"Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort Study.","authors":"I-Lin Tsai, Chien-Yu Lin, Po-Lan Su, Chien-Chung Lin, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Cheng-Ta Yang, Chiao-En Wu","doi":"10.1177/11795549251348367","DOIUrl":null,"url":null,"abstract":"Background: S-1, an oral chemotherapy combining tegafur, gimeracil, and oteracil, has shown efficacy comparable with docetaxel for advanced non-small cell lung cancer (NSCLC) in clinical trials. However, its real-world effectiveness and safety remain underexplored.Methods: This retrospective cohort study was conducted at 2 tertiary referral centers: National Cheng Kung University Hospital (NCKUH) from July 1, 2012 to July 1, 2023 (last follow-up in October 31, 2023) and Linkou Chang Gung Memorial Hospital (CGMH) from February 1, 2020 to January 31, 2023 (last follow-up in August 31, 2023). The study included 132 NSCLC patients receiving S-1 monotherapy (77 from CGMH and 55 from NCKUH). After excluding 31 patients with less than 2 weeks of treatment, 101 patients were analyzed.Results: The objective response rate (ORR) was 7.9%, and the disease control rate (DCR) was 44%. Median progression-free survival (PFS) and overall survival (OS) were 2.6 and 6.0 months, respectively. First-line or second-line S-1 therapy significantly improved DCR (61.1% vs 33.8%, P = .008) and PFS (4.2 vs 2.3 months, P < .001) compared with third-line or later use. Cox regression analysis confirmed earlier-line S-1 treatment (⩽ 2) as an independent predictor for PFS (hazard ratio: 2.01, 95% confidence interval: 1.15-3.51, P = .014). Severe adverse events (grade ⩾ 3) occurred in 7.9% of cases.Conclusions: S-1 monotherapy demonstrated comparable effectiveness and manageable toxicity in real-world settings, with significantly better outcomes when used as first-line or second-line treatment in NSCLC.","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"19 ","pages":"11795549251348367"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231965/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11795549251348367","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: S-1, an oral chemotherapy combining tegafur, gimeracil, and oteracil, has shown efficacy comparable with docetaxel for advanced non-small cell lung cancer (NSCLC) in clinical trials. However, its real-world effectiveness and safety remain underexplored.

Methods: This retrospective cohort study was conducted at 2 tertiary referral centers: National Cheng Kung University Hospital (NCKUH) from July 1, 2012 to July 1, 2023 (last follow-up in October 31, 2023) and Linkou Chang Gung Memorial Hospital (CGMH) from February 1, 2020 to January 31, 2023 (last follow-up in August 31, 2023). The study included 132 NSCLC patients receiving S-1 monotherapy (77 from CGMH and 55 from NCKUH). After excluding 31 patients with less than 2 weeks of treatment, 101 patients were analyzed.

Results: The objective response rate (ORR) was 7.9%, and the disease control rate (DCR) was 44%. Median progression-free survival (PFS) and overall survival (OS) were 2.6 and 6.0 months, respectively. First-line or second-line S-1 therapy significantly improved DCR (61.1% vs 33.8%, P = .008) and PFS (4.2 vs 2.3 months, P < .001) compared with third-line or later use. Cox regression analysis confirmed earlier-line S-1 treatment (⩽ 2) as an independent predictor for PFS (hazard ratio: 2.01, 95% confidence interval: 1.15-3.51, P = .014). Severe adverse events (grade ⩾ 3) occurred in 7.9% of cases.

Conclusions: S-1 monotherapy demonstrated comparable effectiveness and manageable toxicity in real-world settings, with significantly better outcomes when used as first-line or second-line treatment in NSCLC.

Abstract Image

查看原文本刊更多论文

S-1单药治疗非小细胞肺癌的实际疗效和安全性：来自多中心回顾性队列研究的见解

背景：S-1是一种联合替加富、吉美拉西和奥他拉西的口服化疗药物，在临床试验中显示出与多西他赛相当的治疗晚期非小细胞肺癌（NSCLC）的疗效。然而，其在现实世界中的有效性和安全性仍有待进一步研究。方法：本回顾性队列研究在两家三级转诊中心进行：国立成功大学医院（NCKUH） 2012年7月1日至2023年7月1日（最后一次随访为2023年10月31日）和林口长庚纪念医院（CGMH） 2020年2月1日至2023年1月31日（最后一次随访为2023年8月31日）。该研究纳入了132例接受S-1单药治疗的NSCLC患者（77例来自CGMH， 55例来自NCKUH）。在排除31例治疗时间少于2周的患者后，对101例患者进行分析。结果：客观有效率（ORR）为7.9%，疾病控制率（DCR）为44%。中位无进展生存期（PFS）和总生存期（OS）分别为2.6个月和6.0个月。一线或二线S-1治疗显著改善了DCR （61.1% vs 33.8%, P = 0.008）和PFS （4.2 vs 2.3个月，P = 0.014）。7.9%的病例发生了严重不良事件（等级大于或等于3）。结论：S-1单药治疗在现实环境中显示出相当的有效性和可控的毒性，作为NSCLC的一线或二线治疗具有明显更好的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Medicine Insights-Oncology Medicine-Oncology

CiteScore

2.40

自引率

4.50%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological and epidemiological topics. Of particular but not exclusive importance are molecular biology, clinical interventions, controlled trials, therapeutics, pharmacology and drug delivery, and techniques of cancer surgery. The journal welcomes unsolicited article proposals.